Trade Dispute In New Arenas
7/8/2007 Beijing, China Arianna Eun Jung Cha Courant.com Every few days, Houston businessman Richard Weissenborn receives injections of a radical new cancer drug at a hospital in Beijing. The treatment aims to check his head and neck cancers by replacing mutant genes with good copies. The treatment is still experimental in the United States, but in China, it was approved for marketing after a few years of testing. The Chinese scientists behind the drug, Gendicine, see it as a milestone in the country's efforts to catch up with the West, proof that China can develop some of the world's most advanced medicine. But a company in the United States says the Chinese drug is basically stolen property, rushed to market with inadequate testing and in violation of patent rights. The dispute is the latest clash between the two countries in the broad field known as intellectual property. China in recent decades has prospered largely because of a talent for copying. The country duplicates goods others created, but figures out how to make them more cheaply. For years, that tactic focused on items like watches, purses and DVDs. But increasingly, China is moving up the value chain, copying such high-value goods and services as architectural techniques, cars and drugs. The dispute over the gene-therapy drug is especially revealing in that scientific innovation is a pillar of American business. If other countries can learn to beat the United States to market with drugs and other technologically advanced goods, that could spell economic [...]